ArticleJournal of molecular histology2026
Bone transport accelerates diabetic foot ulcer healing via TGF-β1-mediated angiogenic and osteo-immune coupling.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remote periosteal distraction promotes ischemic diabetic foot wound repair associated with VEGF/VEGFR2-related angiogenic responses.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diabetic foot ulcer (DFU), often complicated by peripheral artery disease and local ischemia, remains a major clinical challenge. Bone transport (BT) is a surgical technique known to promote both osteogenesis and angiogenesis, and has shown promise in facilitating DFU healing. However, the underlying molecular mechanisms, especially the role of the TGF‑β1 signaling pathway, are not yet fully understood. Seventy-five Sprague-Dawley rats with ischemic diabetic foot ulcers (DFUs) were randomly assigned to three groups: sham (osteotomy without distraction), BT, and BT with TGF-β1 pathway inhibition (BTI). Wound healing was evaluated using serial wound measurement and histology. The contribution of the TGF-β1 pathway was assessed using proteomics, ELISA, RT-qPCR, and immunohistochemistry.The BT group exhibited accelerated wound closure, greater dermal thickness, and enhanced re-epithelialization compared to the sham and BTI groups. Proteomic analysis revealed upregulation of TGF-β1 and TGFBR1 expression in BT-treated wounds, accompanied by activation of the TGF-β1/TGFBR1 pathway. Notably, BT also triggered a systemic immune response, including complement activation and inflammatory regulation, indicating the involvement of both innate and adaptive immunity. Consistently, serum concentrations of TGF-β1 and VEGF were increased in the BT group than the other two groups, paralleled by elevated local expression of TGF-β1, TGFBR1, VEGF, and α-SMA at the wound sites. These pro-healing effects were markedly attenuated in the BTI group. BT stimulated the release of osteokines and growth factors, including TGF-β1, which activated the TGF-β1/TGFBR1 pathway to couple osteogenesis with angiogenesis and immunomodulation, thereby promoting diabetic wound repair. Targeting the TGF-β1/TGFBR1 pathway is likely a promising treatment for enhancing diabetic wound healing.
Indexed as
Identifiers
42043593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.